Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
FDA approval
Fierce Pharma
FDA greenlights RevMed’s pancreatic cancer gamechanger
Following dynamite data that earned a standing ovation at ASCO, RevMed's star Ras inhibitor daraxonrasib has been approved by the FDA.
Darren Incorvaia
Aug 26, 2026 11:30am
FDA clears Abbott’s sensor for capturing diabetic ketoacidosis
Aug 26, 2026 8:25am
FDA clears Lantheus’ Alzheimer’s PET imaging agent Tauklarify
Aug 17, 2026 7:51am
Samsung hearing aid features for its ear buds earn FDA clearance
Aug 12, 2026 8:02am
Fierce Pharma
Celcuity set to be Big Pharma 'strategic target' after approval
Jul 14, 2026 4:56pm
FDA clears Dexcom’s Stelo OTC glucose monitor for children
Jun 16, 2026 8:15am
